Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor

Phase 2

Completed

• Conditions: Neuroendocrine Tumor
• Interventions: Drug: Pazopanib

• Registration Number: NCT01099540
• Lead Sponsor: Samsung Medical Center

Brief Summary

To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-04
• Study First Submitted: 2010-04-06
• Study First Submitted QC: 2010-04-06
• Study First Posted: 2010-04-07
• Primary Completion: 2012-03
• Study Completion: 2013-03
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-28
• Last Update Posted: 2015-12-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 37

Inclusion Criteria

• low to intermediate grade neuroendocrine tumor not amenable to surgery or local therapy

Exclusion Criteria

• poorly differentiated (high grade or anaplastic)/small cell, pheochromocytoma

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pazopanib	Pazopanib	-

Primary Outcome Measures

Name	Time	Method
response rate	1~2 year

Trial Locations

Locations (1)

Samsung Cancer Center; 🇰🇷 Seoul, Korea, Republic of